Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.
This combination of email and password didn't match our records. Your account might not be activated. If so, please click on the link we sent you via email. You can also request a password reset or a new activation email using the links below.
: FAGR BB, IVA FP, SOF BB, ENRGY BB
: BREB BB, OPTI BB, EXM BB, SOLB BB, WDP BB, DEME BB, JDEP NA, ENRGY BB
: FAST NA, EXO NA
First-half result numbers overshadowed by the various milestones achieved over the past two years by its biocontrol solution (with final approval of the active substance by the European Commission and the signing of a strategic distribution agreement with Koppert) now enables them to launch its commercialisation in 2026. The US EPA (Environmental Protection Agency) decision on the application for federal marketing authorisation in the US for AXPERA, which has been delayed for reasons beyond Amoéba's own control, is expected in 1Q26. We also welcome the interest in its cosmetic ingredient, bo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.